TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15307550

Group type: EXPERIMENTAL
Intervention: PMEA coated circuit and oxygenator (group X)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Heparin coated circuit and oxygenator (group H)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Noncoated circuit and oxygenator (group N)
Number of subjects: 30
Study: 11148715

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 0
Study: 9060560

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) filgrastim; 5 microg/kg/d
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 8405743

Group type: EXPERIMENTAL
Intervention: Intramuscular injection into the thigh (IMT)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection into the abdominal wall (SCA)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection into the thigh (SCT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (SCA and IMT)
Number of subjects: 55
Study: 3776949

Group type: EXPERIMENTAL
Intervention: 20% ethanol (6 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (1% ethanol)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (20 mg/kg iv)
Number of subjects: 10
Study: 30354975

Group type: EXPERIMENTAL
Intervention: Intrathecal Baclofen (ITB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional Medical Management (CMM)
Number of subjects: 60
Study: 27049100

Group type: EXPERIMENTAL
Intervention: Intranasal T-LysYal
Number of subjects: 89

Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 89
Study: 24642785

Group type: EXPERIMENTAL
Intervention: High-calcium (CAL) supplementation (1400 mg of calcium)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (CON) supplementation (400 mg of calcium)
Number of subjects: 13
Study: 22638306

Group type: EXPERIMENTAL
Intervention: Hospital-sponsored bags with no formula at source (intervention group)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Industry-sponsored formula sample packs (control group)
Number of subjects: 527
Study: 20516658

Group type: EXPERIMENTAL
Intervention: Low-dose beta-carotene (30 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose beta-carotene (90 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline (control)
Number of subjects: 30
Study: 18541125

Group type: EXPERIMENTAL
Intervention: Maxacalcitol ointment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maxacalcitol lotion
Number of subjects: 12
Study: 15825531

Group type: EXPERIMENTAL
Intervention: TPD ophthalmic solution (0.5% tropicamide, 0.5% phenylephrine, 0.1% diclofenac)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Individual solutions (0.5% tropicamide/0.5% phenylephrine, 5% phenylephrine, 0.1% diclofenac)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: TPD ophthalmic solution
Number of subjects: 38
Study: 12806380

Group type: EXPERIMENTAL
Intervention: Gyrus bipolar electrovaporization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gyrus bipolar electrovaporization and TURP
Number of subjects: 0
Study: 12577372

Group type: EXPERIMENTAL
Intervention: Tripterygium polyglucoside (TII)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 30
Study: 9463561

Group type: EXPERIMENTAL
Intervention: Inhalative beclomethasone
Number of subjects: 57

Group type: COMPARATOR
Intervention: Oral prednisolone (10 mg per day)
Number of subjects: 57
Study: 7944840

Group type: EXPERIMENTAL
Intervention: Inappropriate medication use
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Subjects using three or more prescription drugs
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Subjects with depressive symptoms
Number of subjects: 414
Study: 3295625

Group type: EXPERIMENTAL
Intervention: Low-dose human recombinant interferon-alpha-2c (Hr-IFn alpha 2c) at 1.2 X 10(6) IU/m2 for 28 days, subcutaneously (s.c.)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ultra-low dose treatment of Hr IFn-2c at 1.2 X 10(5) IU/m2, s.c. daily increasing to a well-tolerated dose
Number of subjects: 97
Study: 31777234

Group type: EXPERIMENTAL
Intervention: Buqi Yixue needling
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cilostazol (50 mg/time, 2 times/d) and Epalrestat (50 mg/time, 3 times/d)
Number of subjects: 86
Study: 29121625

Group type: EXPERIMENTAL
Intervention: Face-to-face delivery of the Green Prescription
Number of subjects: 138
Study: 25131892

Group type: EXPERIMENTAL
Intervention: Advance directive and proxy opinion available and concordant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advance directive opposed, proxy favored intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advance directive favored intervention, proxy opposed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discordance between instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No instruction (control)
Number of subjects: 0
Study: 22209741

Group type: EXPERIMENTAL
Intervention: High glycemic index (GI) diet
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: High glycemic load (GL) diet
Number of subjects: 511

Group type: COMPARATOR
Intervention: Low glycemic index (GI) diet
Number of subjects: 511

Group type: COMPARATOR
Intervention: Low glycemic load (GL) diet
Number of subjects: 511
Study: 22152723

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg subcutaneously at 8-week intervals
Number of subjects: 35
Study: 20297714

Group type: EXPERIMENTAL
Intervention: midazolam plus ketamine (MK)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: promethazine plus ketamine (PK)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: midazolam plus tramadol (MT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: promethazine plus tramadol (PT)
Number of subjects: 36
Study: 16502769

Group type: EXPERIMENTAL
Intervention: Ramipril test formulation from Laboratórios Biosintética Ltda (5 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Triatec formulation from Aventis Pharma (5 mg)
Number of subjects: 26
Study: 15208585

Group type: EXPERIMENTAL
Intervention: Albuterol metered‐dose inhalers (16 cumulative puffs, doubled at 15-minute intervals)
Number of subjects: 15
Study: 11085051

Group type: EXPERIMENTAL
Intervention: HRT + K (TTS natural estrogens 50 micrograms/day with progestin and Kava‐Kava extract at a dose of 100 mg, n=13)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ERT + K (TTS natural estrogens 50 micrograms/day and Kava‐Kava extract at a dose of 100 mg, n=11)
Number of subjects: 40

Group type: COMPARATOR
Intervention: HRT (TTS natural estrogens 50 micrograms/day with progestin and a placebo product, n=9)
Number of subjects: 40

Group type: COMPARATOR
Intervention: ERT (TTS natural estrogens 50 micrograms/day and a placebo product, n=7)
Number of subjects: 40
Study: 9330431

Group type: EXPERIMENTAL
Intervention: Stimulus levels allocated using a randomized design based on a generalized Polya urn model.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unimodal and symmetric allocation of stimulus levels around the unknown median of the stimulus-response curve.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychophysical studies conducted in neurophysiology in humans.
Number of subjects: 0
Study: 7689778

Group type: EXPERIMENTAL
Intervention: Reduced doses of alkylating agents
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intensified protocols supported by hematopoietic growth factors
Number of subjects: 35
Study: 31649304

Group type: EXPERIMENTAL
Intervention: Psilocybin (315 μg/kg PO)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 28541926

Group type: EXPERIMENTAL
Intervention: Statin + omega-3 PUFA 2.52 g/day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Statin + omega-3 PUFA 2.52 g/day + CoQ10 200 mg/day
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (unaltered statin therapy)
Number of subjects: 105
Study: 25407083

Group type: EXPERIMENTAL
Intervention: Human fibroblast-derived dermal substitute plus standard wound care
Number of subjects: 314

Group type: COMPARATOR
Intervention: Conventional care alone
Number of subjects: 314
Study: 24348043

Group type: EXPERIMENTAL
Intervention: Vitamin E tocotrienol-rich fraction (TRF) 180 mg tocotrienols, 40 mg tocopherols
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (0.48 mg tocotrienols, 0.88 mg tocopherols)
Number of subjects: 81
Study: 21513530

Group type: EXPERIMENTAL
Intervention: School-based lifestyle intervention programme including weekly lifestyle-lessons for children, teacher training, and parent training.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: School-based lifestyle intervention programme
Number of subjects: 15
Study: 18840702

Group type: EXPERIMENTAL
Intervention: Exposure to disability and hearing loss narratives
Number of subjects: 35

Group type: COMPARATOR
Intervention: No exposure to disability and hearing loss narratives
Number of subjects: 35
Study: 16942618

Group type: EXPERIMENTAL
Intervention: Candesartan/HCTZ (16 mg/12.5 mg) with passive compliance monitoring (Group B)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Candesartan/HCTZ (16 mg/12.5 mg) with DRC intervention program (Group C)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Combination therapy (Group A)
Number of subjects: 62
Study: 12946764

Group type: EXPERIMENTAL
Intervention: Cystoplasty with cecum and ascending colon (Group 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sigmoid cystoplasty (Group 2)
Number of subjects: 28
Study: 10861338

Group type: EXPERIMENTAL
Intervention: L-Carnitine (L-C) 2 g twice daily for 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (lactose) 2 g twice daily for 8 weeks
Number of subjects: 36
Study: 9182742

Group type: EXPERIMENTAL
Intervention: Scaling and root planing + 25% tetracycline fibers (S&T)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Scaling and root planing + 2% minocycline gel (S&Mi)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Scaling and root planing + 25% metronidazole gel (S&Me)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Scaling and root planing alone (S)
Number of subjects: 54
Study: 8237295

Group type: EXPERIMENTAL
Intervention: 10 cm H2O PEEP
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 15 cm H2O PEEP
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 5 cm H2O PEEP
Number of subjects: 11

Group type: COMPARATOR
Intervention: 0 cm H2O PEEP (baseline)
Number of subjects: 11
Study: 2422004

Group type: EXPERIMENTAL
Intervention: Org 2766 (synthetic ACTH4-9 analog), 40 mg daily for 6 months
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Org 2766 (synthetic ACTH4-9 analog)
Number of subjects: 77
Study: 30212849

Group type: EXPERIMENTAL
Intervention: Abstinence-optimized treatment (A-OT): 3 weeks of prequit mini-lozenges, 26 weeks of nicotine patch + mini-lozenges, three in-person and eight phone counseling sessions, and 7-11 automated calls to prompt medication use
Number of subjects: 623

Group type: COMPARATOR
Intervention: Recommended usual care (R-UC): 10 min of in-person counseling, 8 weeks of nicotine patch, and referral to quitline services
Number of subjects: 623
Study: 27958384

Group type: EXPERIMENTAL
Intervention: EUS-guided ethanol injection (n=10)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: EUS-guided iodine-125 seed implantation (n=13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Second EUS-guided intervention (n=5)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Surgical resection (n=1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Radiotherapy (n=2)
Number of subjects: 26
Study: 23856100

Group type: EXPERIMENTAL
Intervention: 5 mg/day of oral olanzapine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study: 22800696

Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao capsules (2 g/d) for 28 days after operation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo capsules (2 g/d) for 28 days after operation
Number of subjects: 200
Study: 20367775

Group type: EXPERIMENTAL
Intervention: Alcohol condition (target blood alcohol level = 0.10%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (sober women)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported sexual arousal
Number of subjects: 0
Study: 17928026

Group type: EXPERIMENTAL
Intervention: Training on identifying crowded letters
Number of subjects: 0
Study: 15173694

Group type: EXPERIMENTAL
Intervention: Peri‐procedural hemofiltration
Number of subjects: 114

Group type: COMPARATOR
Intervention: Saline hydration
Number of subjects: 114
Study: 11719594

Group type: EXPERIMENTAL
Intervention: HLA-G*0104 or HLA-G*0105N allele presence
Number of subjects: 113
Study: 9131355

Group type: EXPERIMENTAL
Intervention: Approach to skillful, safe, and appropriate use of touch synthesized with an awareness of the breath
Number of subjects: 0
Study: 7957532

Group type: EXPERIMENTAL
Intervention: Esmolol at 100 micrograms.kg‐1 BW.min‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esmolol at 250 micrograms.kg‐1 BW.min‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esmolol at 500 micrograms.kg‐1 BW.min‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esmolol (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esmolol (500 micrograms.kg‐1 BW.min‐1)
Number of subjects: 0
Study: 3300711

Group type: EXPERIMENTAL
Intervention: Postoperative CMF chemotherapy
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Postoperative tamoxifen
Number of subjects: 1022

Group type: COMPARATOR
Intervention: No adjuvant therapy (Control)
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Postoperative radiation therapy (Control)
Number of subjects: 1022
Study: 29098255

Group type: EXPERIMENTAL
Intervention: Flap group
Number of subjects: 160

Group type: COMPARATOR
Intervention: Flapless group
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 27288803

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 87
Study: 24914427

Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 186
Study: 22473347

Group type: EXPERIMENTAL
Intervention: 0.1 ppm ozonated water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 0
Study: 19325497

Group type: EXPERIMENTAL
Intervention: Divalproex extended-release (ER)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Long-term study
Number of subjects: 150
Study: 17470670

Group type: EXPERIMENTAL
Intervention: Nocturnal auto-titrating CPAP
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 26
Study: 16130876

Group type: COMPARATOR
Intervention: Distilled water (DW) without sealer
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Distilled water (DW) + AH Plus
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Distilled water (DW) + Endofill
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl without sealer
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + AH Plus
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + Endofill
Number of subjects: 72
Study: 12029205

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Heart-median ratio of 123I-MIBG uptake
Number of subjects: 58
Study: 10079452

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (bupivacaine 0.75%)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Paraoocular anesthesia
Number of subjects: 245
Study: 7573090

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg hs (average dose 29.5 mg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 2076392

Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg per day)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study: 6769452

Group type: EXPERIMENTAL
Intervention: Carbonated bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride
Number of subjects: 40
Study: 30601990

Group type: EXPERIMENTAL
Intervention: Cervical headgear (CH) treatment in early group (EG)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cervical headgear (CH) treatment in late group (LG)
Number of subjects: 67
Study: 28002391

Group type: EXPERIMENTAL
Intervention: Test formula (bovine milk-derived oligosaccharides and Bifidobacterium animalis ssp lactis)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Control formula (without bovine milk-derived oligosaccharides and B. lactis)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Test formula
Number of subjects: 413
Study: 25823975

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg with enzyme‐inducing AEDs
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg with enzyme‐inducing AEDs
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg with non‐inducing AEDs
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg with non‐inducing AEDs
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Perampanel during extension (Weeks 1‐52)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 143
Study: 22752539

Group type: EXPERIMENTAL
Intervention: Energy conservation programme
Number of subjects: 23

Group type: COMPARATOR
Intervention: Peer support group
Number of subjects: 23
Study: 21063868

Group type: EXPERIMENTAL
Intervention: Red Bull® Energy Drink (250 ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Uninterrupted driving
Number of subjects: 24
Study: 19728932

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Number of subjects: 75
Study: 17920499

Group type: EXPERIMENTAL
Intervention: Facemask with expansion (FMEXP)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Facemask only (FM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 15291290

Group type: EXPERIMENTAL
Intervention: Midwife management
Number of subjects: 1352

Group type: COMPARATOR
Intervention: Physician management
Number of subjects: 1352
Study: 12785046

Group type: EXPERIMENTAL
Intervention: Residents who wrote down their patients' pain score as a fifth vital sign in the medical record
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonintervention group (residents who did not write down pain scores)
Number of subjects: 0
Study: 9645979

Group type: EXPERIMENTAL
Intervention: 619C89 (up to 2.5 mg/kg loading plus 1.25 mg/kg/8 h maintenance)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 619C89 (doses below 2 mg/kg + 1 mg/kg/8 h)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 619C89 (2 mg/kg/8 h or more)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 619C89
Number of subjects: 48
Study: 7907174

Group type: EXPERIMENTAL
Intervention: Zidovudine and didanosine combination therapy
Number of subjects: 68
Study: 2790863

Group type: EXPERIMENTAL
Intervention: 5 mM ZnCl2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mM ZnCl2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 mM ZnCl2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 mM ZnCl2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 mM ZnCl2 (in heavy plaque formers)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 mM ZnCl2 (in heavy plaque formers)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 mM ZnCl2 (on acid production)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 mM ZnCl2 (on acid production)
Number of subjects: 16
Study: 362874

Group type: EXPERIMENTAL
Intervention: phenylpropanolamine/aromatic oil syrup
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: phenylpropanolamine syrup
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: aromatic oil syrup
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo syrup
Number of subjects: 80
Study: 29951911

Group type: EXPERIMENTAL
Intervention: BladderScan® BVI 9400
Number of subjects: 407

Group type: COMPARATOR
Intervention: Transurethral catheterization
Number of subjects: 407
Study: 28969994

Group type: EXPERIMENTAL
Intervention: Static thermal testing using cold stimuli
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Random heat pulses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Temporal summation at the heat pain threshold
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pressure pain stimuli
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Temporal summation pain score changes using 2 pinprick probes (256 and 512 mN)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Delayed recovery
Number of subjects: 30
Study: 26267983

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg taken orally 30 minutes before endometrial biopsy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23201831

Group type: EXPERIMENTAL
Intervention: Processed food pattern (highest tertile)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Whole food pattern (not explicitly mentioned in outcomes)
Number of subjects: 249
Study: 20530522

Group type: EXPERIMENTAL
Intervention: Prasterone (DHEA) 200 mg/day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 18946771

Group type: EXPERIMENTAL
Intervention: Tailored intervention employing motivational interviewing and telephone follow‐up
Number of subjects: 543

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 543
Study: 16181530

Group type: EXPERIMENTAL
Intervention: Yufeining pills taken orally for half a year
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no medicine)
Number of subjects: 36